VB-111: Targeting Cancer

VBL’s lead product candidate from our oncology program, VB-111, is a targeted anti-cancer gene-based biologic agent that we are developing for solid tumor indications, with clinical trials in rGBM, ovarian cancer and thyroid cancer.

VB-111 is administered systemically and is both tissue- and condition-specific, allowing for targeted and limited gene expression in endothelial cells, the thin layer of cells that lines the interior surface of blood vessels undergoing angiogenesis.

Following the successful completion of a Phase 1/2 clinical trial, VB-111 has been advanced into tumor specific, repeat-dose trials including:  

  • Recurrent Glioblastoma (rGBM) – VBL Therapeutics’ pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA. The trial is conducted in the US, Canada and Israel.
  • Ovarian cancerVBL completed a Phase 1/2 clinical trial in recurrent ovarian cancer, which combined VB-111 therapy with paclitaxel, a common chemotherapeutic agent used to treat ovarian cancer, to evaluate safety and efficacy in this indication. The company launched a Phase 3 study in platinum-resistant Ovarian Cancer in December 2017.
  • Differentiated Thyroid cancer – VBL conducted an open-label Phase 2 clinical trial to evaluate safety and efficacy of VB-111 in advanced, recently progressive differentiated thyroid cancer that is unresponsive to radioactive iodine. 
  • Lung cancer – VBL plans to conduct an exploratory study of VB-111 in combination with a checkpoint inhibitor (immuno-therapy) in non-small-cell lung cancer. The trial launch is expected in 1Q 2018.